hs-10353
Small moleculeexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 27, 2021 (NCT05195203)
Timeline
Indications
Mechanism of action
- GABA receptor alpha-1 subunitMODULATOR
GABRA1 modulator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05937867 | Phase 2 | Aug 31, 2023 | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| NCT05938179 | Phase 2 | Aug 31, 2023 | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| NCT05195203 | Phase 1 | Jan 27, 2021 | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | For profit | 3 | 3 | 2 | 2021 |
1 organizations
Page 1 / 1